We showed that two PPRHs designed against the ERBB2 gene were able to silence the ERBB2 gene and protein expression and cause a significant decrease in the viability of breast cancer cells in vitro and tumor growth in vivo, either alone or in combination with trastuzumab. Here, ERBB2 is linked to neoplasm.